REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Monoclonal Antibody Or Fragment Thereof (i.e., Produced By Any Cloning Technology) > Binds Receptor > Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.)Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190053 - Treament of lupus nephritis with anti-cd40l compounds This invention relates to methods for treatment of nephritis associated with immune complex disease using anti-CD40L compounds. According to one embodiment of this invention, anti-CD40L compounds are administered to a patient with immune complex disease who has received a kidney allograft, to inhibit the development of immune complex glomerulonephritis within ... 08/16/07 - 20070190052 - Regulatory cd8cells induced with anti-cd3 antibody The invention provides methods for treating autoimmunity, for reestablishing tolerance, and for generally dampening or suppressing the activation state of the immune system. The methods involve the induction or activation of a particular regulatory T cell population, characterized by its expression of CD8, CD25 and Foxp3. ... 08/16/07 - 20070190051 - Antibodies to cd40 The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies ... 08/09/07 - 20070184051 - Anti cd44 antibodies for eradicating stem cells The present invention provides the use of an anti-CD44 antibody, a (Fab′)2, Fab, Fab′ fragment thereof, an IgG or IgM isotype thereof, in the preparation of a medicament for eradicating pathological stem cells in cancer therapy, and more specifically in acute myeloid leukaemia therapy. ... 08/09/07 - 20070184050 - Stable water-based medicinal preparation containing antibody A stable liquid medical formulation containing an antibody is provided, which contains a therapeutically effective amount of an antibody in a glutamate buffer and/or a citrate buffer and has a pH between 4.0 and 6.0. ... 08/02/07 - 20070178094 - Hybrid peptides modulate the immune response The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide ... 08/02/07 - 20070178093 - Lymphocytes; methods Provided are methods of modulating activity of regulatory T cells, CD4+ T cells, and CD8+ T cells. Also provided are methods of treating immune disorders. ... 08/02/07 - 20070178092 - Humanized anti-cd3 specific antibodies Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression. ... 08/02/07 - 20070178091 - Combination therapy The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a ... 08/02/07 - 20070178090 - Breast endothelial cell expression patterns To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that ... 07/26/07 - 20070172478 - Methods of treating skin disorders Methods of treating skin disorders are provided. ... 07/26/07 - 20070172477 - Use of soluble cd14 for treatment of diseases Use of soluble CD14 (sCD14) for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a chronic inflammation condition and a clinical disorder associated with insulin resistance in an animal or a human. Examples of diseases include type 2 diabetes mellitus, obesity, metabolic syndrome, arteriosclerotic ... 07/19/07 - 20070166309 - Optimized anti-cd30 antibodies An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody. ... 07/19/07 - 20070166308 - Antibodies to madcam The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, ... 07/19/07 - 20070166307 - Suppression of transplant rejection The present invention relates to a transplant rejection in an animal suppressed by administration of an antibody directed at a cell surface antigen selected from the group consisting of CD4, CD8, CD154, LFA-1, CD80, CD86 and ICAM-1, preferably an anti-CD4 antibody, together with a non-cellular protein antigen to generate in ... 07/12/07 - 20070160604 - Methods of identifying compounds capable of modulating t cell immune responses involving sema4a protein The invention relates to a novel costimulatory pathway mediated by a member of the semaphorin protein family, Sema4A, which is selectively expressed on the surface of dendritic cells. In addition, the invention relates to the use of Sema4A protein and protein derivatives in a method for the identification of immunomodulatory ... 07/05/07 - 20070154477 - Humanized anti-cd3 specific antibodies Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression. ... 07/05/07 - 20070154476 - Receptor coupling agents and therapeutic uses thereof Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed. ... 06/28/07 - 20070148171 - Optimized anti-cd30 antibodies An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody. ... 06/28/07 - 20070148170 - Fc variants with optimized fc receptor binding properties The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties. ... 06/21/07 - 20070141054 - Anti-a33 antibody The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant ... 06/21/07 - 20070141053 - Treatment of inflammatory respiratory diseases The present invention relates to the use of immune modulatory factors which act at CD114, CD116, and or CDw131 to successfully treat various forms of inflammatory respiratory disease, including, but not limited to ARDS, IRDS, SARS, PRRS, PEARS and SIRS. ... 06/21/07 - 20070141052 - Fc region variants The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease. ... 06/14/07 - 20070134241 - Humanized anti-cd3 specific antibodies Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression. ... 06/14/07 - 20070134240 - Use of a cd28 binding substance for making a pharmaceutical composition The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells. ... 06/14/07 - 20070134239 - Nucleotide and protein sequences of vertebrate delta genes and methods based thereon The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs ... 06/14/07 - 20070134238 - Modulation of t cell differentiation for the treatment of t helper cell mediated diseases The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype ... 06/07/07 - 20070128190 - Anti-alpha2 integrin antibodies and their uses The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that ... 06/07/07 - 20070128189 - Il-21 receptor antagonists Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2Rγ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an ... 06/07/07 - 20070128188 - Novel stra6 polypeptides The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention ... 05/31/07 - 20070122410 - Use of an active substance binding to cd28 for producing a pharmaceutical composition for the treatment of b-cll The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the ... 05/31/07 - 20070122409 - Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor antagonist. ... 05/31/07 - 20070122408 - Fc labeling for immunostaining and immunotargeting The present invention discloses methods of labeling Fc portions of antibodies, or fusion proteins incorporating Fc portions of antibodies, so that they can be used in immunostaining or immunolabeling procedures. A wide variety of labels can be used. A linker can be used between the label and the protein to ... 05/31/07 - 20070122407 - Isolated nucleic acids, vectors and host cells encoding erbb3 antibodies Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; ... 05/31/07 - 20070122406 - Optimized proteins that target ep-cam Humanized Ep-CAM-targeting antibodies and methods of making and using the same are provided. ... 05/24/07 - 20070116703 - Isolated mammalian membrane proteins; related agents Nucleic acids encoding various lymphocyte cell proteins from mammalian, including primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. ... 05/17/07 - 20070110746 - Pharmaceutical composition for treatment of immunological disorders Disclosed is a pharmaceutical composition for treating immunological disorders by inhibiting the activation of T lymphocytes, comprising, as active ingredients, two or more selected from the group consisting of a substance capable of blocking binding of an MHC (Major Histocompatibility Complex) Class II molecule and a receptor thereof, a substance ... 05/10/07 - 20070104709 - T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds The invention relates to compounds that specifically bind a T1R1/T1R3 or T1R2/T1R3 receptor or fragments or sub-units thereof. The present invention also relates to the use of hetero-oligomeric and chimeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet ... 05/03/07 - 20070098720 - Cd40-binding apc-activating molecules Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing ... 05/03/07 - 20070098719 - Gitr binding molecules and uses therefor The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression ... 05/03/07 - 20070098718 - Methods of therapy for b cell-related cancers Methods of treating a human subject for a cancer characterized by neoplastic B cell growth are provided. The methods comprise administering combination antibody therapy to the subject, where an effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof in combination with an anti-CD20 antibody or antigenbinding fragment thereof ... 05/03/07 - 20070098717 - Methods of therapy for solid tumors expressing the cd40 cell-surface antigen Methods of therapy are provided for treating a subject for a solid tumor that comprises carcinoma cells expressing the CD40 cell-surface antigen. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a subject in need thereof. The antagonist anti-CD40 antibody or ... 04/26/07 - 20070092516 - Antibody preparation An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants ... 04/26/07 - 20070092515 - Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin Methods to treat secondary injury resulting from spinal cord injury using polypeptide compositions that specifically bind to CD11d are disclosed. ... 04/19/07 - 20070086998 - Therapeutic human anti-mhc class ii antibodies and their uses The instant invention relates to methods, compositions, uses related to the compositions and pharmaceutical packages for treating a disorder involving cells expressing MHC class II antigens using a combination of a human antibody-based antigen-binding domain that binds to a human Class II MHC molecule, and an antibody-based antigen-binding domain that ... 04/12/07 - 20070081994 - Chimeric heteromultimer adhesins Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed ... 04/12/07 - 20070081993 - Pharmaceutical composition comprising a bispecific antibody for epcam The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 ... 04/05/07 - 20070077247 - Receptor on the surface of activated t-cells: act-4 The invention provides purified ACT-4 receptor polypeptides, antibodies against these polypeptides and nucleic acids encoding ACT-4 receptor polypeptides. Also provided are methods of diagnosis and treatment using the same. ACT-4 receptors are preferentially expressed on the surface of activated CD4+ T-cells. ACT-4 receptors are usually expressed at low levels on ... 04/05/07 - 20070077246 - Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such ... 04/05/07 - 20070077245 - Notch mutations leading to increased receptor signaling The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increased receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for ... 03/22/07 - 20070065438 - Methods of inducing and maintaining immune tolerance Provided are methods of enhancing and maintaining immune tolerance by modulation of CD200 or CD200R. Provided are antagonists thereof including antibodies. ... 03/22/07 - 20070065437 - Anti-cd3 antibody formulations This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages of anti-CD3 antibodies, as well as to methods for using such formulations and dosages. ... 03/22/07 - 20070065436 - Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response. ... 03/22/07 - 20070065435 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease ... 03/22/07 - 20070065434 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease ... 03/22/07 - 20070065433 - Methods and compositions for the treatment of meconium aspiration syndrome A method for preventing or treating meconium aspiration syndrome (“MAS”) by administering a meconium aspiration syndrome preventing or treating amount of one or more complement inhibitors to a patient likely to develop or suffering from MAS. The complement inhibitors are preferably antibodies that bind to and inhibit complement proteins involved ... 03/15/07 - 20070059308 - Human monoclonal antibodies against membrane proteins Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat ... 03/15/07 - 20070059307 - Biological products There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the ... 03/15/07 - 20070059306 - B-cell reduction using cd37-specific and cd20-specific binding molecules The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further ... 03/08/07 - 20070053904 - Antibodies having diagnostic, preventive, therapeutic, and other uses The invention provides isolated nucleic acids encoding a variety of proteins and nucleic acids having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, ... 03/08/07 - 20070053903 - Methods of using phhla2 to co-stimulate t-cells The invention provides pHHLA2 co-receptor polypeptides and functional fragments, antibodies to same, isolated polynucleotides encoding same, vectors containing the polynucleotides, cells containing the vectors. Methods of making and using these co-stimulatory pHHLA2 co-receptors molecules are also disclosed. ... 03/01/07 - 20070048310 - Human ataxin-1-like polypeptide imx97018 This invention relates to IMX97018, a new members of the human ataxin-1-like polypeptide family, methods of making such polypeptides, and to methods of using them to diagnose and treat neurological conditions and to identify compounds that alter IMX97018 polypeptide activities. ... 03/01/07 - 20070048309 - Nucleic acid encoding cytokine receptor zcytor17 Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ... 03/01/07 - 20070048308 - Nucleic acid encoding cytokine receptor zcytor17 Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ... 03/01/07 - 20070048307 - Nucleic acid encoding cytokine receptor zcytor17 Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zyctor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ... 03/01/07 - 20070048306 - Method for generating anti-variable region monoclonal antibodies Methods for generating anti-variable region monoclonal antibodies in rodents are disclosed. The anti-variable region mAbs are useful as therapeutic agents, diagnostic agents or research reagents. ... 03/01/07 - 20070048305 - Cd147 binding molecules as therapeutics In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in ... 02/22/07 - 20070041971 - Methods for predicting development of auto-immune diseases and treatment of same The present invention provides a new method for the prediction of, or diagnosis of, auto-immune diseases, thereby alerting the subject to the presence of, or propensity to develop, an auto-immune disease so that preventative or therapeutic regiments may be initiated or changed so as to treat, modulate or prevent expansion ... 02/15/07 - 20070036786 - Method of treating autoimmune disease using humanized anti-cd16a antibodies CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia. ... 02/08/07 - 20070031408 - Anti-ccr5 antibody The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit ... 02/08/07 - 20070031407 - Peptide or protein containing a c'-d loop of the cd28 receptor family The invention relates to a protein or peptide comprising the C′-D loop of a member of the CD28 family, uses thereof and mAbs obtainable therefrom. ... 02/08/07 - 20070031406 - Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis Methods and products are described for inducing B cell apoptosis, using antibody-induced apoptosis. Specifically, polyclonal antiserum or one or more monoclonal antibodies, either alone or in combination, as well as fragments or variants thereof are employed in the methods and products of the present invention. These antibodies, or fragments or ... 02/01/07 - 20070025990 - Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one ... 02/01/07 - 20070025989 - Administration of agents for the treatment of inflammation A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the ... 02/01/07 - 20070025988 - Method for treating lupus A method of treating lupus in a subject eligible for treatment is provided involving administering an effective amount of an antibody that binds to a B-cell surface marker to the subject to provide an initial exposure and a subsequent exposure to the antibody within certain dosing regimens and an article ... 02/01/07 - 20070025987 - Method for treating vasculitis A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of ... 01/25/07 - 20070020265 - Immunotherapy of autoimmune disorders using antibodies which target b-cells Antibodies that bind with a B-cell antigen provide an effective means to treat autoinmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies. ... 01/25/07 - 20070020264 - Serum albumin binding peptides for tumor targeting Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion. ... 01/25/07 - 20070020263 - Medicine containing genetically modified antibody against chemokine receptor ccr4 A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided. ... 01/18/07 - 20070014798 - Antibodies to dendritc cells and human dendritic cell populations and uses thereof Described are novel antibodies specifically recognizing a distinct population of human dendritic cells (DCs) and methods of isolating said DCs using said antibodies. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are vectors comprising said polynucleotides as well ... 01/18/07 - 20070014797 - Method for treating sjogren's syndrome A method of treating Sjögren's syndrome in a patient eligible for treatment is provided involving administering an effective amount of an antagonist that binds to a B-cell surface marker to the patient to provide significant improvement over baseline in two or more of dryness, fatigue, and joint pain on a ... 01/18/07 - 20070014796 - Method for the production of non-immunogenic proteins A target protein is rendered less immunogenic to a given species by (a) determining at least part of the amino acid sequence of the target protein; (b) identifying in the amino acid sequence one or more potential epitopes for T-cells (“T-cell epitopes”) of the given species; and (c) modifying the ... 01/18/07 - 20070014795 - Compositions and methods for enhanced dendritic cell maturation and function This invention relates to compositions comprising an agent, which inhibits signaling via the FcγRIIB receptor and an agent which stimulates or enhances signaling via an FcγRI receptor, an FcγRIIa receptor, an FcγRIII receptor, or a combination thereof. The invention also provides for the use of such compositions in stimulating or ... 01/11/07 - 20070009523 - Polypeptide variants with altered effector function The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. ... 01/11/07 - 20070009522 - Anti-rhesus d monoclonal antibodies The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease ... 01/11/07 - 20070009521 - Human tumor necrosis factor tr21 and methods based thereon The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 ... 01/11/07 - 20070009520 - Antibodies to ocif-binding molecules A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. ... 01/11/07 - 20070009519 - Immunoregulatory antibodies and uses thereof A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration. ... 01/11/07 - 20070009518 - Methods for treating fibrotic conditions The present invention is directed to methods for treating fibrosis conditions, such as liver, kidney and lung fibrosis, as well as fibrosis conditions of other tissues of the body. The methods of the invention comprise administering to a patient in need of such treatment a therapeutically effective amount of a ... 01/11/07 - 20070009517 - Method of inducing immune tolerance Methods for inducing tolerance to a transplant in a subject are disclosed. The methods comprise administering multiple doses of a therapeutically effective amount of a CD40 antagonist alone or in combination with a CD86 antagonist, wherein the first dose of the antagonist is given before or at the time of ... 01/11/07 - 20070009516 - Immune response-associated proteins Various embodiments of the invention provide human immune response associated proteins (IRAP) and polynucleotides which identify and encode IRAP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of IRAP. ... 01/11/07 - 20070009515 - Inflammatory skin disease-related slurp-2 gene and utilization thereof The present inventors used microarrays to identify a novel gene from cDNA clones showing significantly different gene expression in normal tissues compared to psoriasis lesion tissues. This gene was named secretory Ly-6/uPAR-related protein-2 (SLURP-2). Quantitative real-time RT-PCR analysis using total RNA extract was used to compare SLURP-2 gene expression between ... 12/28/06 - 20060292144 - Human disintegrin protein Provided is a new disintegrin polypeptide, methods of making such polypeptides, and methods of using them to treat disintegrin-associated disorders and conditions and to identify agents that modulate Metalloproteinase-Disintegrin polypeptide activities. ... 12/28/06 - 20060292143 - Novel t-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein ... 12/28/06 - 20060292142 - Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. “Humanized” anti-CD3 mAbs, such as gOKT3-5 and gOKT3-7, have been shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated, ... 12/28/06 - 20060292141 - Inhibition of factor b and the alternative complement pathway for treatment of traumatic brain injury and related conditions Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those ... 12/21/06 - 20060286104 - Superagonistic anti-cd28 antibodies The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the ... 12/14/06 - 20060280741 - Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering ... 12/14/06 - 20060280740 - Compositions and methods for regulating nk cell activity The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and ... 12/07/06 - 20060275292 - Fully human anti-cd3 monoclonal antibodies Non-toxic anti-CD3 antibody is useful for the treatment, prevention, and reversal of human autoimmune disease. Anti-CD3 antibody is generated by immunizing xenogenic mice capable of developing fully human antibodies. Because the inventive antibodies are not derived from other species, they do not the invoke the immune responses typically associated with ... 12/07/06 - 20060275291 - Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, ... 12/07/06 - 20060275290 - Active or passive immunization against proapoptotic neurotrophins for the treatment and/or prevention of neurodegenerative diseases The present invention relates to novel methods for combating cell degeneration or dysfunction resulting from neuroinflammatory conditions. The invention especially relates to the use, in the preparation of a medicament for the treatment of neurodegenerative disease associated with neuroinflammation, of an immunogenic compound which is capable of inducing an immune ... 12/07/06 - 20060275289 - Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient It is possible to use a screening system using the inhibition of CD81 gene expression, the inhibition of CD81 expression or the inhibition of its function (activity) as an indication in searching for a drug for preventing, ameliorating or treating IBD. Also, anti-CD81 antibody is highly efficacious as the active ... 11/30/06 - 20060269548 - Lymphatic endothelial cells materials and methods The present invention is directed to methods and compositions for isolating lymphatic endothelial cells from a mixed population of cells. More particularly, the inventors have found that certain antibodies that recognize the extracellular domain of VEGFR-3 can be used to specifically isolated lymphatic endothelial cells substantially free of other contaminating ... 11/23/06 - 20060263358 - Method for reducing sepsis or cardiogenic shock associated with myocardial injury Methods of reducing sepsis or cardiogenic shock in patients experiencing myocardial injury are described. More specifically, this disclosure relates to the administration of a C5-C9 terminal complement inhibitor to patients who have had coronary artery bypass grafting or an acute myocardial infarction thereby reducing the incidence of sepsis. ... 11/23/06 - 20060263357 - Anti-cd19 antibody therapy for autoimmune disease The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the ... 11/23/06 - 20060263356 - Antibodies against il-13 receptor alpha1 and uses thereof An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, ... 11/16/06 - 20060257404 - Modulators of the p2y10 receptor useful in altering t lymphocyte function The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting ... 11/16/06 - 20060257403 - Methods for treating and preventing fibrosis The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or ... 11/16/06 - 20060257402 - Use of soluble cd164 in inflammatory and/or autoimmune disorders The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of humans CD164, in particular for treating inflammatory and/or autoimmune disorders. ... 11/16/06 - 20060257401 - Sensitizing cells for apoptosis by selectively blocking cytokines The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, ... 11/09/06 - 20060251654 - Method for treatment of malignant and infectious chronic diseases The present invention relates to methods of treatment useful in chronic diseases, by means of breaking tolerance to self-antigens and increasing autoimmune response against these antigens. More particularly, the present invention relates to methods useful in the treatment of tumors that are growth dependent on the Epidermal Growth Factor. The ... 11/09/06 - 20060251653 - Methods for treating interleukin-6 related diseases A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R). ... 11/09/06 - 20060251652 - Cd20 binding molecules The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention ... 11/09/06 - 20060251651 - Antagonist and agonist which bind to a strong binding site of chemokine receptor An antagonist or an agonist which binds to a strong binding site of CCR5; a preventive and/or therapeutic agent for an allergic disease, an inflammatory disease, an immune disease and/or a cancer which comprises the same; a method for screening a compound which binds to a strong binding site of ... 11/02/06 - 20060246068 - Polypeptides having a triggering nk activity and biological applications The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO: 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, ... 11/02/06 - 20060246067 - Immunomodulatory constructs and their uses The invention relates to immunomodulators. In particular the invention relates to specific immunomodulators based on the superantigen SMEZ-2 and more particularly based on mutants of the superantigen SMEZ-2, which are adapted to target antigen-presenting-cells for the purpose of enhancing or suppressing a host immune response. ... 11/02/06 - 20060246066 - Cleavable reagents for specific delivery to disease sites A therapeutic reagent to control one or more reactions of the immune system in a host, or to deliver anti-tumour agents, or disease treatment agents to the host. The therapeutic reagent comprises a regulatory moiety and a carrier protein that inactivates or substantially reduces the activity of the regulatory moiety. ... 10/26/06 - 20060240010 - Methods of modulating cd200 receptors Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders. ... 10/26/06 - 20060240009 - Liposome composition for improved intracellular delivery of a therapeutic agent A liposomal composition and a method of using the same for achieving intracellular delivery of a liposome-entrapped agent is described. The liposomes are composed of a pH sensitive lipid and include a targeting ligand to direct the liposomes to a target cell. The liposomes also include a stabilizing component, such ... 10/26/06 - 20060240008 - Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNFα-inhibitor. ... 10/26/06 - 20060240007 - Method for treating dementia or alzheimer's disease Methods for treating Alzheimer's disease (AD) or dementia using a CD20 antibody are described. Articles of manufacture for use in such methods are also described. ... 10/26/06 - 20060240006 - Novel antibody structures derived from human germline sequences In order to provide necessary information for the production of complete human monoclonal antibodies capable of human CD152 (CTLA-4) binding, the primary structures of heavy and light chains have been elucidated. The novel amino acid sequence of identified heavy and light chains are derived from VH3 and Vλ germline genes, ... 10/26/06 - 20060240005 - Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with alloreactive natural killer cells in order to enhance ... 10/19/06 - 20060233798 - Methods for inhibiting hiv-1 infection This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to ... 10/19/06 - 20060233797 - Treatment of inflammatory bowel disease (ibd) The present invention concerns treatment of IBD, especially ulcerative colitis (UC), with an antibody that binds to CD20. ... 10/19/06 - 20060233796 - Method of modulating memory effector t-cells and compositions This invention relates to methods of using inhibitors of the CD2/LFA-3 interaction in treating conditions characterized by the presence of activated T cells in mammals, including humans. Such conditions include inflammatory bowel diseases, psoriatic arthritis, rheumatoid arthritis, and multiple sclerosis. ... 10/19/06 - 20060233795 - Methods for selectively modulating a th2-type response within a population of activated cd4+ t cells Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells are provided. The methods of the invention involve contacting the CD4+ T cells with an agent which modulates a B7-2-induced signal in the CD4+ T cells, such that the Th2-type response is modulated. Methods for ... 10/19/06 - 20060233794 - Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical ... 10/19/06 - 20060233793 - Use of anti-cd100 antibodies The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as ... 10/12/06 - 20060228357 - Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as ... 10/12/06 - 20060228356 - Composition and method for treating lupus nephritis The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in ... 10/12/06 - 20060228355 - Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor The present invention relates to antibodies directed to Epidermal Growth Factor Receptor that are single domain antibodies Camelidae VHHs. It further relates to methods of of use of said polypeptides. ... 09/28/06 - 20060216291 - Glycoprotein vi and uses thereof The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been ... 09/28/06 - 20060216290 - Diagnostics and therapeutics for diseases associated with g-protein coupled protease activated receptor 1 (par1) The invention provides a human PAR1 which is associated with the cardiovascular disorders, dermatological disorders, orders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and ... 09/14/06 - 20060204497 - Cytotoxicity mediation of cells evidencing surface expression of cd63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The ... 08/31/06 - 20060193858 - Cloning and expression of human slap-2: a novel sh2/ sh3 domain-containing human slap homologue having immune cell-specific expression The present invention describes a newly discovered full-length polynucleotide encoding an SH2/SH3 domain-containing adapter protein, called hSLAP-2, cloned, isolated and identified. Also described are the hSLAP-2 polypeptide sequence, expression vectors, host cells, agonists, antagonists, anti-sense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Methods for ... 08/31/06 - 20060193857 - Modulation of fc gamma receptors for optimizing immunotherapy The present invention relates to methods for modulating the maturation of dendritic cells. In particular, the invention provides methods for (a) promoting the maturation of dendritic cells thereby producing mature dendritic cells, and (b) preventing the maturation of dendritic cells thereby preventing maturation and producing tolerogenic dendritic cells. The present ... 08/31/06 - 20060193856 - Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such ... 08/31/06 - 20060193855 - Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenting cells. Such compositions are able to transform a seemingly ineffective ... 08/17/06 - 20060182745 - Anti-cd63 antibodies and methods of use thereof CD63 inhibition of IgE-mediated degranulation in mast cells and in vivo inhibition of allergic processes are described. The invention is drawn to methods of treating allergic conditions and anaphylaxis in a mammal comprising administering an effective amount of an agent that inhibits a function of CD63. ... 08/17/06 - 20060182744 - Anti-cd137 antibody as an agent in the treatment of cancer and glycosylation variants thereof The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as an anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of ... 08/10/06 - 20060177443 - Integrin antagonists The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration, and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are ... 08/10/06 - 20060177442 - Method of treating cd30 positive lymphomas Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and proteasome inhibitors in combination are disclosed. ... 07/27/06 - 20060165694 - Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be ... 07/27/06 - 20060165693 - Humanized anti-cd3 specific antibodies Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression. ... 07/27/06 - 20060165692 - Humanized anti-cd3 specific antibodies Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression. ... 07/27/06 - 20060165691 - Humanized anti-cd3 specific antibodies Novel aglycosylated antibodies having a binding affinity for the Cd3 antigen complex are of value for use in therapy, particularly in immunosuppression. ... 07/27/06 - 20060165690 - Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies We describe a conjugate comprising an anti-CD40 or anti-CD28 antibody and antigen wherein said conjugate has low antibody valency and including methods to prepare said conjugate. ... 07/27/06 - 20060165689 - Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 Provided are compositions and methods for the prevention and treatment of mammalian disorders that are ameliorated by modulation of effects on phagocyte and lymphoid cell populations and T-cell immune response cDNA 7 (TIRC7) activity in certain cells. Furthermore, improved methods for the production of immunoglobulins to a desired antigen are ... 07/27/06 - 20060165688 - Remedies for pemphigus containing cd40l antogonist as the active ingredient The present invention concerns developing a remedy for treating pemphigus by administering a CD40L antagonist to patients with pemphigus such as pemphigus vulgaris or pemphigus foliaceus, and a preventive agent for preventing the development of pemphigus by preventively administering a CD40L antagonist. Antagonists such as an anti-CD40L antibody that inhibit ... 07/20/06 - 20060159686 - Natural killer cell activating factor ii The invention relates to NKAF II polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to ... 07/20/06 - 20060159685 - B7-related nucleic acids and polypeptides useful for immunomodulation The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated ... 07/20/06 - 20060159684 - Compositions and methods for the threatment of sepsis The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing ... 07/20/06 - 20060159683 - Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment. ... 07/20/06 - 20060159682 - Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs ... 07/13/06 - 20060153844 - Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs The present invention includes use of a biological response modifier (BRM) to modulate an immune response in a subject while avoiding or limiting common side-effects associate with BRM use. The BRMs of the present invention can be injected into a secondary lymphatic organ of the subject or into an area ... 07/13/06 - 20060153843 - Method of immunomodulation The present invention relates generally to a method for modulating the activity of cells of the immune system, including stimulator and responder cells and to agents useful therefor. More particularly, the present invention relates to a method for preventing or down-regulating one or more functional activities of stimulator and responder ... 06/29/06 - 20060140944 - Novel polypeptides involved in immune response Novel polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders. ... 06/29/06 - 20060140943 - Immunotherapy using modulators of notch signalling There is provided a use of a modulator of Notch signalling for the preparation of a medicament for treatment of Graft Versus Host Disease (GVHD) and diseases and conditions caused by or associated with transplants such as organ, tissue and/or cell transplants (e.g. bone marrow transplants), wherein the modulator is ... 06/22/06 - 20060134110 - Cd55-interaction partners and the uses thereof The invention relates to the use of a binding member which binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to SCR1 and SCR2 of CD55 and neutralising CD55 and making cancer cells susceptible to ... 06/15/06 - 20060127400 - Activation of regulatory t cells by alpha-melanocyte stimulating hormone The invention encompasses a method of down-regulating a T cell-mediated immune response, through activation or T cell receptor (TCR) stimulation of antigen-primed T cells in the presence of alpha-melanocyte stimulating hormone (α-MSH), which may be optionally enhanced by adding transforming growth factor-β2 (TGF-β2) approximately 4-6 hours after the start of ... 06/15/06 - 20060127399 - Compositions and methods for inducing chimerism in a subject Prevention of autoimmune disease and induction of transplantation tolerance in a recipient can be achieved by induction of mixed chimerism via bone marrow transplantation (BMT), but this procedure requires total body irradiation (TBI)-conditioning of the recipient. The toxicity of radiation and potential for graft versus host disease (GVHD) prevents its ... 06/15/06 - 20060127398 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or ... 06/08/06 - 20060121032 - Optimized anti-cd20 monoclonal antibodies having fc variants The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes. ... 06/08/06 - 20060121031 - Relay vaccine The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes ... 06/08/06 - 20060121030 - Use of cd 137 antagonists for the treatment of tumors The present invention relates to the therapy of tumors through neutralisation of CD137 or inhibition of CD137 expression of CD137 antagonising molecules. Furthermore, the present invention provides the use of CD137 or agonistic anti-CD307 ligand antibodies for the treatment of conditions characterised by overactive immune reactions. ... 06/08/06 - 20060121029 - Method and composition for regulating the activity of regulatory t cells The present invention provides a composition and method of regulating the activity of regulatory T cells. The present invention relates to a composition containing an antigen recognized by CD4+CD25+ regulatory T cells or an expression vector encoding such an antigen and a method of controlling an immune response from a ... 06/01/06 - 20060115476 - Antibodies anti-c5 component of the complement system and their use The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies ... 05/25/06 - 20060110387 - Method for treating vasculitis A method of treating anti-neutrophil cytoplasmic antibodies-associated vasculitis (ANCA-associated vasculitis) in a patient eligible for treatment is provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the patient in a dose of about 400 mg to 1.3 grams at a frequency of ... 05/18/06 - 20060104977 - Methods of therapy and diagnosis using immunotargeting of cd84hy1-expressing cells Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of ... 05/18/06 - 20060104976 - Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells The present invention relates to the identification and use of high efficacy vaccine antigens which modulate antigen presenting cells. ... 05/18/06 - 20060104975 - C-type lectin binding molecules, identification and uses thereof C-type lectins are involved in the binding of many different types of carbohydrates. Considering their diversity in kind and expression of different types of cells, the influence of such binding is very diverse and dependent among others on the type of cell, the environment of the cell and the type ... 05/18/06 - 20060104974 - Cd147 binding molecules as therapeutics In accordance with the present invention, we have discovered that the molecule CD147 as expressed on certain cells, such as T-cells, B-cells, and/or monocytes, can be utilized for the treatment of a variety of diseases. In particular, we have demonstrated that antibodies that bind to CD147 and that result in ... 04/20/06 - 20060083739 - Treating prostate cancer with anti-erbb2 antibodies The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies. ... 04/06/06 - 20060073147 - Gamma-1 and gamma-3 anti-human cd23 monoclonal antibodies and use thereof as therapeutics Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies. ... 04/06/06 - 20060073146 - Uses of agonists and antagonists to modulate activity of tnf-related molecules Methods of using one or more agonists or antagonists to modulate activity of the members of the TNF and TNFR families referred to as TALL-1, APRIL, TACI, and BCMA are provided. The methods include in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions ... 04/06/06 - 20060073145 - Methods and compositions for inhibiting cd14 mediated cell activation This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated ... 03/30/06 - 20060067935 - Compositions and methods for inhibiting drusen complement components c3a and c5a for the treatment of age-related macular degeneration Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and/or prevention of neovascular disease are ... 03/23/06 - 20060062787 - Method for treating sjogren's syndrome A method of treating Sjögren's syndrome in a patient eligible for treatment is provided involving administering an effective amount of an antagonist that binds to a B-cell surface marker to the patient to provide significant improvement over baseline in two or more of dryness, fatigue, and joint pain on a ... 02/23/06 - 20060039909 - Human cd28 specific monoclonal antibodies for antigen-non-specific activation of t-lymphocytes The invention teaches human-compatible monoclonal antibodies which are specific against human CD28 and human T-lymphocytes of several to all subgroups to activate without occupancy of an antigen receptor of the human T-lymphocytes and thus antigen-non-specifically. ... 02/16/06 - 20060034844 - Stimulation of t cells against self antigens using ctla-4 blocking agents Stimulation of T cells to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-cell response against self antigens. ... 01/12/06 - 20060008457 - Use of an active substance binding to cd28 for producing a pharmaceutical composition for the treatment of b-cll The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the ... 01/05/06 - 20060002933 - Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. “Humanized” anti-CD3 mAbs, such as gOKT3-5 and gOKT3-7, have been shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated, ... 01/05/06 - 20060002932 - Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity The present invention provides a method of enhancing an immune response in a subject, comprising administering to the subject a reagent that targets a cell having immunosuppressive activity, in an amount effective in reducing the immunosuppressive activity of the cell, thereby enhancing an immune response in the subject. Also provided ... 01/05/06 - 20060002931 - Antibodies of angiogenesis inhibiting domains cd148 Anti-CD148 antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind CD148 epitopes and activate CD148 function, such as inhibition of angiogenesis. Epitopes that can be used to activate ... 01/05/06 - 20060002930 - Treatment of disorders The present invention concerns treatment of polychondritis or mononeuritis multiplex in a mammal with an effective amount of an antibody that binds to CD20, optionally also with another agent that treats such disorders in an effective amount. ... 01/05/06 - 20060002929 - Monoclonal antibodies Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chains of monoclonal antibodies. ... 01/05/06 - 20060002928 - Methods and molecules for modulating an immune response A molecule capable of potentiating immune responses and modifying existing states of immune responsiveness is described. Also described are compositions containing the molecule, as well as methods for using the molecule and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, ... 01/05/06 - 20060002927 - Use of anti-cd1 antibodies for the modulation of immune responses The invention provides methods for the administration of an anti-CD 1 antibody for the treatment or prevention of a variety of disorders, such as autoimmune disease, viral infection, bacterial infection, parasitic infection, infection by a eukaryotic pathogen, allergy, asthma, inflammatory condition, graft versus host disease, graft rejection, immunodeficiency disease, spontaneous ... 12/29/05 - 20050287142 - Remedies or preventives for rheumatoid arthritis This invention provides a therapeutic agent for treating or preventing rheumatoid arthritis containing a LARC inhibitor or a LARC receptor inhibitor. ... 12/29/05 - 20050287141 - Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease An isolated molecule which comprises an antibody specifically bindable with a binding affinity below 20 nanomolar, preferably below 10 nanomolar, to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen and optionally further comprises an identifiable or therapeutic moiety conjugated to the antibody. ... 12/29/05 - 20050287140 - Antibodies to angiogenesis inhibiting domains of cd148 The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD 148. Compositions of the invention include: anti-CD148 antibodies, ... 12/22/05 - 20050281818 - Method for the treatment of fibrosis Disclosed is a method of treating fibrosis in a human or animal subject. The method comprises administering to the subject an effective amount of an antibody to an integrin or fragment thereof. ... 12/22/05 - 20050281817 - Method for treating multiple sclerosis A method is provided for administering to a mammal suffering from, or at risk for, multiple sclerosis, an initial dosing of a therapeutically effective amount of an anti-LFA-1 antibody, followed by a subsequent intermittent dosing of a therapeutically effective amount of the anti-LFA-1 antibody wherein the antibody is administered to ... 12/22/05 - 20050281816 - Modular antigen transporter molecules (mat molecules) for modulating immune reactions, associated constructs, methods and uses It is therefore the object of the invention to provide means for supplying any of a wide variety of antigens in a sufficiently targeted manner to their processing site that even better therapeutic and diagnostic use thereof is possible. ... 12/22/05 - 20050281815 - Cd40 splice variants and their uses Disclosed are CD40 splice variant polypeptides and methods of using the CD40 splice variant polypeptides, including in treatment for transplantation. ... 12/15/05 - 20050276805 - Method of modulating the activity of functional immune molecules The invention relates to a method for controlling the activity of an immunologically functional molecules, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having promoted activity. ... 12/08/05 - 20050271662 - Canine cd20 compositions The invention provides canine CD20 nucleotide and protein sequences. These compositions are useful in the diagnosis and treatment of, e.g., CD20+ B-cell lymphoma, immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, and systemic lupus erythematosus (SLE) in canines and felines. ... 12/08/05 - 20050271661 - Methods and reagents for the treatment of immunoinflammatory disorders The invention involves the treatment, prevention, and reduction of immunoinflammatory disorders involving the combination of an agent that increases the signal activity of a glucocorticoid receptor (e.g., glucocorticoid receptor agonist) and an agent that modulates the signaling activity of one or more signaling pathways selected from the NF-κB pathway, NFAT ... 12/08/05 - 20050271660 - Nebulization of monoclonal antibodies for treating pulmonary diseases The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition. ... 12/08/05 - 20050271659 - Novel t-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof Described are generally a T cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein as well as peptides und polypeptides derived therefrom and antibodies recognizing said (poly)peptides. More particularly, peptide and polypeptide as well as antibodies being capable of inhibiting T-cell stimulation through the T-cell membrane protein ... 12/08/05 - 20050271658 - Preventing autoimmune disease The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by administering a CD20 antibody to the subject in an amount to prevent the subject from experiencing one or more symptoms of ... 12/08/05 - 20050271657 - |